CAPTURE VASCULAR INC.
Capture Vascular Inc.’s proprietary platform technology, the MegaVac™ Mechanical Thrombectomy System, is uniquely designed to remove thrombus and emboli throughout the peripheral and coronary vasculature. The unique design and broad indications for use of the MegaVac Mechanical Thrombectomy System makes it appropriate for several key markets, with a total worldwide market opportunity greater than $500M. Capture’s initial focus is peripheral arterial disease and coronary arterial disease. The combination of just these two indications will address a global market of over 250,000 patients annually.